glp 1 and gip dual agonist GIPR/GLP-1R therapies for diabetes weight loss—chemistry, physiology, and clinical applications Mechanisms of action and therapeutic

Originally developed for Type 2 diabetes, these medications have gained FDA approval for obesity, reducing risk for heart disease and kidney disease, and treatment of obstructive sleep apnea within the last three years

It works by increasing brain active compounds or neurotransmitters, including norepinephrine, that affect hunger signals in the brain

A 26-week liraglutide study did not reduce amyloid levels or improve cognition, though it preserved how the brain uses glucose

Common denial reasons are plan exclusion for weight loss medications, non-formulary for your medication, or need for prior diet and exercise program

Finan B, Mller TD, Clemmensen C, et al